Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma

Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma

<p>Supplementary Table S5A. Bulk-level single cell ATAC sequencing analysis showing immediate (short-term) chromatin openings (peaks) in HN30-P cells following CDDP treatment; Supplementary Table S5B. Bulk-level single cell ATAC sequencing analysis showing long-term chromatin openings (peaks)...

詳細記述

保存先:
書誌詳細
第一著者: Abdullah A. Osman (15056323) (author)
その他の著者: Emre Arslan (15056326) (author), Mason Bartels (15056329) (author), Chieko Michikawa (15056332) (author), Antje Lindemann (15056335) (author), Katarzyna Tomczak (15056338) (author), Wangjie Yu (15056341) (author), Vlad Sandulache (15056344) (author), Wencai Ma (15056347) (author), Li Shen (14959241) (author), Jing Wang (14959256) (author), Anand K. Singh (15056350) (author), Mitchell J. Frederick (14959253) (author), Nakia D. Spencer (15056353) (author), Jeffery Kovacs (15056356) (author), Timothy Heffernan (15056359) (author), William F. Symmans (15056362) (author), Kunal Rai (15056365) (author), Jeffrey N. Myers (15026901) (author)
出版事項: 2025
主題:
Cancer
Cancer Risk Factors
Tumor Biology
Molecular and Cellular Biology
Therapeutic Research and Development
Methods and Technology
Drug Resistance
Drug Targets
Epigenetics
Epigenomics
Head, Neck & Oral Cancers
Preclinical Models
Progression, Invasion & Metastasis
Tumor progression
Small Molecule Agents
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
その他の書誌記述
要約:<p>Supplementary Table S5A. Bulk-level single cell ATAC sequencing analysis showing immediate (short-term) chromatin openings (peaks) in HN30-P cells following CDDP treatment; Supplementary Table S5B. Bulk-level single cell ATAC sequencing analysis showing long-term chromatin openings (peaks) gained in cisplatin-resistant HN30-R8 cells following CDDP treatment.</p>

類似資料